LASR$43.83
$44.6851
Chart
Performance
Key Stats
AI LASR Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralnLIGHT, Inc. demonstrates strong potential within its niche industrial and aerospace markets. While its technology is promising, recent financial performance indicates challenges. The company's technicals are mixed, suggesting careful consideration is needed.
Thematic
nLIGHT's focus on advanced laser technology for industrial, microfabrication, and aerospace/defense applications places it within several growing thematic areas. Its products are crucial for applications like advanced manufacturing, medical devices, and directed energy systems.
Fundamental
nLIGHT's financials show revenue growth over time, but the company has consistently reported net losses. While debt levels have decreased, profitability remains a key challenge. The current valuation, considering the losses, warrants scrutiny.
Technical
The stock has shown significant upward momentum over the past 6 months and year-to-date, trading above key moving averages. However, some indicators suggest it might be approaching overbought territory or facing short-term resistance.
| Factor | Score |
|---|---|
| Industrial Automation & Advanced Manufacturing | 85 |
| Aerospace & Defense | 80 |
| Semiconductor Microfabrication | 75 |
| Innovation in Photonics | 80 |
| Supply Chain & Geopolitics | 65 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 20 |
| Growth | 30 |
| Balance Sheet Health | 90 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 50 |
| Volume Confirmation | 70 |
| Support & Resistance | 75 |
| Short-term Indicators | 45 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Recent Price Performance
The stock price has increased by 0.05% in pre-market trading, indicating potential positive sentiment leading into the trading session.
Strong Medium-Term Performance
The stock has shown significant positive performance over the last 6 months (+73.5%) and year-to-date (+87.6%), suggesting strong upward momentum.
Bearish Points (8)
Consistent Net Losses
The company has reported net losses in all analyzed annual periods (2021-2024) and most quarterly periods, with negative EPS on a TTM basis (-$1.14).
Negative Profit Margins
The company has consistently reported negative net margins, with the latest annual figure for 2024 at -30.6% and quarterly for Q4 2024 at -52.7%.
Calendar
August 2025
8
Next Earnings Date
H: $-0.07
A: $-0.09
L: $-0.12
H: 56.00M
A: 55.24M
L: 53.87M
Profile
nLIGHT, Inc. designs, develops, manufactures, and sells semiconductor and fiber lasers for industrial, microfabrication, and aerospace and defense applications. The company operates through two segments, Laser Products and Advanced Development. It offers semiconductor lasers with various ranges of power levels, wavelengths, and output fiber sizes; and programmable and serviceable fiber lasers for use in industrial, aerospace, and defense applications. The company also provides fiber amplifiers, beam combination, and control systems for use in high-energy laser systems in directed energy applications. It sells its products through direct sales force in the United States, China, South Korea, and European countries, as well as through independent sales representatives and distributors in Asia, Australia, Europe, the Middle East, and South America. The company was formerly known as nLight Photonics Corporation and changed its name to nLIGHT, Inc. in January 2016. nLIGHT, Inc. was incorporated in 2000 and is headquartered in Camas, Washington.
Seasonals
Price Target
17.17 USD
The 39 analysts offering 1 year price forecasts for LASR have a max estimate of 24.00 and a min estimate of 12.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
TELA Bio acquired PolarityTE (LASR) in November 2023. As the acquiring entity, TELA Bio now encompasses PolarityTE's regenerative medicine assets and pipeline, making it the most directly related company and the successor to LASR's operations.
Weight: 95
A leading regenerative medicine company that develops and commercializes advanced wound care and surgical biologics products. Its focus on skin and soft tissue regeneration directly aligns with PolarityTE's historical core business (e.g., SkinTE).
Weight: 90
Specializes in advanced wound care and surgical solutions using human amniotic tissue allografts. MIMEDX directly competes in the regenerative wound healing and soft tissue repair space, a primary area of PolarityTE's past operations.
Weight: 88
A global medical technology company providing regenerative technologies, wound care, and surgical solutions. Its portfolio includes products for skin and tissue repair, making it a key peer in the broader regenerative and reconstructive market.